Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imagion Biosystems Ltd. ( (AU:IBX) ) has shared an announcement.
Imagion Biosystems has initiated the manufacturing process for its MagSense® HER2 Imaging Agent, a crucial step for the Phase 2 clinical study targeting HER2+ breast cancer. This advancement marks progress towards filing an Investigational New Drug application with the US FDA and signifies the company’s commitment to enhancing diagnostic accuracy for over 400,000 global HER2 breast cancer patients annually. By securing the necessary funds and scheduling production, Imagion is positioned to meet its next development milestone, although additional funding will be required for subsequent phases.
More about Imagion Biosystems Ltd.
Imagion Biosystems is a biotechnology company leveraging nanotechnology to develop non-radioactive and precision diagnostic molecular imaging technology aimed at early and specific detection of cancer and other diseases.
YTD Price Performance: -17.39%
Average Trading Volume: 1,230,032
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$3.83M
Find detailed analytics on IBX stock on TipRanks’ Stock Analysis page.